Spike SARS-CoV-2 mRNA expresses spike protein (S protein) of SARS-CoV-2 virus. The S protein on the surface of SARS-CoV-2 is a major antigen and its engagement with human ACE2 receptor plays an essential role in viral entry into host cells. The main candidate for COVID-19 vaccine development is the SARS-CoV-2 spike protein.
Yaohai Bio-Pharma offers unmodified or N1Ψ modified Spike SARS-CoV-2 mRNA, with Cap1 structure, optimized codons, engineered UTR and 110nt polyA tail, to improve mRNA stability and translation efficiency.
Product
Spike SARS-CoV-2 mRNA, Cap1, poly(A) tail, unmodified or modified mRNA
Product |
Spike SARS-CoV-2 mRNA |
Cat. No | mP005 |
RNA Content | 100 µg~10 mg (OD260) |
Purity | A260/A280 |
Identify and Purity | Agarose Gel Electrophoresis (AGE) |
5’Cap | Cap1 |
3’ poly(A) tail | 110±5 nt |
Base Modification | Unmodified, N1Ψ |
Buffer | RNase free water (liquid) |
Shipping | Ship with dry ice; or under ambient temperature |
Storage |
● Liquid, at or below -20°C ● Lyophilized powder, at 4°C |
Application |
Antigen gene |
Other Customizable Options
5' Cap |
● Uncapped ● Cap0, co-capped ● Cap1, co-capped ● Cap1, enzymatic capping |
5’ UTR/3’ UTR |
● Nature UTR sequence ● Mutant/Engineered UTR sequence |
3' PolyA Tail |
● 100A ~120A Tail (recommended) ● Segmented polyA tail ● Other custom tail |
Modified nucleosides |
● Unmodified bases, ● Pseudouridine (Ψ), ● N1-Methylpseudouridine (N1Ψ), ● 5-methylcytosine (m5C), ● 5-methyluridine (m5U), ● 5-methoxyuridine (5moU), ● 2-thiouridine (s2U), ● 2′-O-methyl-U ● Others |
mRNA Preparation and Cell Expression
Taking linearized plasmid DNA (pDNA) harboring Spike SARS-CoV-2 mRNA coding genes as IVT template, we obtained pure Spike SARS-CoV-2 mRNA transcripts by co-transcriptional capping and purification, with cap1 structure and N1Ψ modification.
Pure Spike SARS-CoV-2 mRNA (1 μg) mixed with a commercial transfection reagent was transfected into 293T cells in a 96 well plate. And Western blotting (WB) was performed after 24 hours.
Expression of Spike SARS CoV-2 mRNA in 293T cells